Soll, Dominik
Bischoff, Philip
Frisch, Anne
Jensen, Marie
Karadeniz, Zehra
Mogl, Martina T.
Horst, David
Penzkofer, Tobias
Spranger, Joachim
Keilholz, Ulrich
Mai, Knut
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 27 August 2023
Accepted: 9 February 2024
First Online: 22 February 2024
Declarations
:
: The study protocol was approved by the Institutional Review Board of the Charité Medical School (EA1/238/22). Informed consent was not necessary according to state legislations (Berliner Landeskrankenhausgesetz (LKG) of September 18, 2011, § 25). All the analyses were conducted in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: T.P. was supported by the Berlin Institute of Health (Clinician Scientist Grant, Platform Grant), Ministry of Education and Research (BMBF, 01KX2021, 68GX21001A), German Research Foundation (DFG, SFB 1340/2), European Union (H2020: 952172, DIGITAL:101100633) and reports research agreements (no personal payments, outside of submitted work) with AGO, Aprea AB, ARCAGY-GINECO, Astellas Pharma Global Inc. (APGD), Astra Zeneca, Clovis Oncology, Inc., Dohme Corp, Holaira, Incyte Corporation, Karyopharm, Lion Biotechnologies, Inc., MedImmune, Merck Sharp, Millennium Pharmaceuticals, Inc., Morphotec Inc., NovoCure Ltd., PharmaMar S.A. and PharmaMar USA, Inc., Roche, Siemens Healthineers, and TESARO Inc., and fees for a book translation (Elsevier).P.B. is participant in the BIH Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the Berlin Institute of Health at Charité (BIH).All other authors declare no competing interests.We declare that there are no conflicts of interest that could be perceived as prejudicing the impartiality of the research reported.